| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2019: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
The oral cavity is dominated by both mucosal and systemic immune systems, due to the presence of immunoglobulin (Ig)A antibodies (Abs) in saliva and IgG Abs in gingival crevicular fluid. Transmucosally administered vaccines allowing the development of both systemic and local immune responses are thus optimal for preventing oral infections. As the basic experiment, optimal concentrations of GroEL as antigen (Ag)and synthetic oligonucleotides containing unmethylated CpG dinucleotide (CpG ODN) as a mucosal adjuvant for sublingual immunization were examined in mice. GroEL-specific immune responses were observed in sublingual immunization with a combination of GroEL plus cholera toxin or GroEL plus CpG ODN. These results suggest that the sublingual administration of GroEL plus CpG ODN is effective for inducing mucosaland systemic Ag-specific Ab responses.
|
